Liver and gut mucosa acetylation of mesalazine in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 11, 2000, Pages 514-522

  Vree, T B ^a   Dammers, E ^a   Exler, P S ^a   Sorgel, F ^a   Bondesen, S ^a   Maes, R A A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acetylation; Gut; Liver; Mesalazine; Pharmacokinetics

Indexed keywords

LIVER ENZYME; MESALAZINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG ABSORPTION; DRUG ACETYLATION; DRUG FORMULATION; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION;

EID: 0033755365     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38514     Document Type: Article

References (27)

1. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid
2. Determination of the pK values of 5-aminosalicylic acid and N-acetylsalicylic acid and comparison of the pH-dependent lipid-water partition coefficients of sulphasalazine and its metabolites
3. A controlled study of 5-acetaminosalicylic acid as an enema in ulcerative colitis
4. Absorption of 5-aminosalicylic acid from colon and rectum
5. Pharmacokinetics of mesalazine in man following administration of intravenous bolus and per os slow-release formulation
6. Intestinal fate of 5-aminosalicylic regional and systemic kinetic studies in relation to inflammatory bowel disease
7. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in chronic inflammatory bowel disease
8. Oro-ileal transit of slow-release 5-aminosalicylic acid
9. Evaluation of an enteric-coated delayed-release mesalazine tablet in patients with inflammatory bowel disease
10. Identification of oxidation products of mesalazine in faeces and the study of their formation in vitro
11. Steady-state disposition of mesalazine following oral dosing
12. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases
13. Metabolism and urinary excretion of mesalazine in healthy volunteers given intravenously or released for absorption at different sites in the gastro-intestinal tract
14. Pharmacokinetics of a mesalazine enteric-coated tablet and suppository dosage form
15. Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease
16. Salicylates for ulcerative colitis. Their mode of action
17. Salicylates for inflammatory bowel disease
18. Double-blind comparisons of 5-aminosalicylic acid and acetyl 5-aminosalicylic acid suppositories in patients with idiopathic proctitis
19. Clinical pharmacokinetics of sulfonamides and their metabolites
20. Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human
21. Clinical pharmacokinetics of sulphonamides
22. Saturable active tubular reabsorption in the renal clearance of mesalazine in human volunteers
23. Monoand biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing
24. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis
25. Absorption of oral mesalazine containing formulations and the influence of famotidine on the absorption